ArticleEJHaem2022

Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Vincent Ribrag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.